Mobile

HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of fluticasone furoate/GW642444 inhalation powder with GW642444m on the annual rate of exacerbations in s...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013063-19

HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of fluticasone furoate/GW642444 inhalation powder with GW642444m on the annual rate of exacerbations in subjects with chronic obstructive pulmonary disease

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate safety and efficacy of FF/GW642444 50mcg/25mcg QD and FF/GW642444 100mcg/25mcg QD and FF/GW642444 200mcg/25mcg QD versus GW642444 25mcg QD on the annual rate of moderate and severe exacerbations in subjects with COPD over a 52 week treatment period. This study will evaluate the contribution of the ICS on reducing the rate of exacerbations when used in combination with a fixed dose of the long-acting beta-agonist (LABA) in patients with COPD.

Critère d'inclusion

  • Patients with Chronic Obstructive Pulmonary Disease (COPD)

Liens